Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Treatment challenges in co-infected HIV and TB children.

Manosuthi W, Wongsawat J.

Indian Pediatr. 2011 Dec;48(12):937-8. No abstract available.

2.

Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.

Shah I, Swaminathan S, Ramachandran G, Kumar AK, Goray A, Chaddha U, Tayal S, Lala M.

Indian Pediatr. 2011 Dec;48(12):943-7. Epub 2011 Mar 15.

3.

Influence of rifampicin on nevirapine plasma concentration in HIV-TB coinfected patients.

Nafrialdi, Nugroho AW, Yunihastuti E, Wiria MS.

Acta Med Indones. 2012 Apr;44(2):135-9.

4.

Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.

Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Shioda T, Khusmith S.

Southeast Asian J Trop Med Public Health. 2012 Jan;43(1):78-88.

PMID:
23082557
5.

Sex differences in nevirapine disposition in HIV-infected patients.

Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F, Meneghetti G, Maserati R.

AIDS. 2003 Nov 7;17(16):2399-400. No abstract available.

PMID:
14571195
6.

Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women.

Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kerr S, Ahluwalia J, Thongpaeng P, Thammajaruk N, Cremers S, Thomas T, Chaithongwongwatthana S, Lange JM, Ananworanich J.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):e50-2. doi: 10.1097/QAI.0000000000000134. No abstract available.

PMID:
24608892
7.

[Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].

Martorell M, López RM, Ribera E, Ruiz I, Tural C, Puig L, Monterde J.

Enferm Infecc Microbiol Clin. 2005 Jun-Jul;23(6):349-52. Spanish.

PMID:
15970167
8.

Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.

Matteelli A, Saleri N, Villani P, Bonkoungou V, Carvalho AC, Kouanda S, Sanou MJ, Simporé J, Monno L, Carosi G, Regazzi M, Dembele M.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):64-9.

PMID:
19731452
9.

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.

Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, Ruxrungtham K.

Clin Infect Dis. 2006 Jul 15;43(2):253-5. Epub 2006 Jun 12.

10.

St. John's wort found to lower nevirapine levels.

[No authors listed]

TreatmentUpdate. 2001 Spring;12(11):6. No abstract available.

PMID:
11570073
11.

Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients.

Cressey TR, Nangola S, Tawon Y, Pattarawarapan M, Lallemant M, Tayapiwatana C.

Antimicrob Agents Chemother. 2007 Sep;51(9):3361-3. Epub 2007 Jul 2.

12.

Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.

Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kriengsinyot R, Ahluwalia J, Thongpaeng P, Gorowara M, Thammajaruk N, Chaithongwongwatthana S, Lange JM, Ananworanich J.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):534-9. doi: 10.1097/QAI.0b013e31827e8f98.

PMID:
23187949
13.

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.

Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.

Antimicrob Agents Chemother. 2013 Feb;57(2):1019-24. doi: 10.1128/AAC.02023-12. Epub 2012 Dec 17.

14.

Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.

van Luin M, Wit FW, Smit C, Rigter IM, Franssen EJ, Richter C, Kroon F, de Wolf F, Burger DM.

Ther Drug Monit. 2011 Feb;33(1):32-9. doi: 10.1097/FTD.0b013e318205b81d.

PMID:
21192311
15.

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD; 2NN Study Group.

Antivir Ther. 2005;10(1):145-55.

PMID:
15751772
16.

Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.

Kou H, Du X, Li Y, Xie J, Qiu Z, Ye M, Fu Q, Han Y, Zhu Z, Li T.

PLoS One. 2013;8(1):e52950. doi: 10.1371/journal.pone.0052950. Epub 2013 Jan 24.

18.

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.

Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, Le Tiec C, Becquemont L, Ouk V, Mentre F, Taburet AM.

Antimicrob Agents Chemother. 2010 Oct;54(10):4432-9. doi: 10.1128/AAC.00512-10. Epub 2010 Aug 9.

19.

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S.

HIV Med. 2008 May;9(5):294-9. doi: 10.1111/j.1468-1293.2008.00563.x.

20.

Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.

Jackson JB, Parsons T, Musoke P, Nakabiito C, Donnell D, Fleming T, Mirochnick M, Mofenson L, Fowler MG, Mmiro F, Guay L.

AIDS. 2006 Jan 9;20(2):217-22.

PMID:
16511414
Items per page

Supplemental Content

Write to the Help Desk